Market Update (NASDAQ:BIIB): Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting

[Business Wire] – Biogen Idec will present data supporting its approved hemophilia therapies at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco, December 6-9. Read more . . . → Read More: Market Update (NASDAQ:BIIB): Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting Similar Articles: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions